

# Sean P Gaine

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5239567/sean-p-gaine-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

13,242  
citations

39  
h-index

105  
g-index

105  
ext. papers

15,954  
ext. citations

7.8  
avg, IF

5.57  
L-index

#	Paper	IF	Citations
97	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , <b>2009</b> , 30, 2493-537	9.5	2531
96	Updated clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S43-S54	15.1	1640
95	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , <b>2020</b> , 41, 543-603	9.5	1043
94	Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1219-63	13.6	919
93	Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , <b>2000</b> , 132, 425-34	8	710
92	Diagnosis and differential assessment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 40S-47S	15.1	651
91	Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. <i>Circulation</i> , <b>2011</b> , 124, 1973-81	16.7	630
90	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2522-33	59.2	521
89	Primary pulmonary hypertension. <i>Lancet, The</i> , <b>1998</b> , 352, 719-25	40	425
88	Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 790-6	10.2	370
87	Dysfunctional voltage-gated K <sup>+</sup> channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. <i>Circulation</i> , <b>1998</b> , 98, 1400-6	16.7	343
86	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. <i>Circulation</i> , <b>2016</b> , 133, 859-71	16.7	331
85	Attenuated K <sup>+</sup> channel gene transcription in primary pulmonary hypertension. <i>Lancet, The</i> , <b>1998</b> , 351, 726-7	40	234
84	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 871-80	3.2	231
83	Pulmonary hypertension in chronic lung disease and hypoxia. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	231
82	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. <i>Circulation</i> , <b>2016</b> , 133, 1761-71	16.7	203
81	Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2003</b> , 41, 293-9	3.1	184

80	End points and clinical trial design in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S97-S107	15.1	166
79	Pulmonary hypertension. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 284, 3160-8	27.4	111
78	Portopulmonary hypertension and the liver transplant candidate. <i>Transplantation</i> , <b>1999</b> , 67, 1087-93	1.8	100
77	Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. <i>Chest</i> , <b>2000</b> , 117, 14-8	5.3	91
76	Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. <i>Transplantation</i> , <b>1998</b> , 65, 457-9	1.8	87
75	emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 1106-13	13.6	82
74	Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2008</b> , 295, L272-84	5.8	67
73	Temporal trends and drug exposures in pulmonary hypertension: an American experience. <i>American Heart Journal</i> , <b>2006</b> , 152, 521-6	4.9	65
72	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	63
71	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	58
70	Role of gremlin in the lung: development and disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2010</b> , 42, 517-23	5.7	55
69	Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. <i>Liver Transplantation</i> , <b>2001</b> , 7, 745-9	4.5	54
68	Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2015</b> , 24, 630-41	9.8	51
67	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 752-763	15.1	50
66	Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217735820	2.7	49
65	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 770-779	5.8	47
64	Poor outcomes associated with drainage of pericardial effusions in patients with pulmonary arterial hypertension. <i>Southern Medical Journal</i> , <b>2008</b> , 101, 490-4	0.6	43
63	COVID-19 induces a hyperactive phenotype in circulating platelets. <i>PLoS Biology</i> , <b>2021</b> , 19, e3001109	9.7	42

62	Combination therapy and new types of agents for pulmonary arterial hypertension. <i>Clinics in Chest Medicine</i> , <b>2007</b> , 28, 169-85, ix	5.3	41
61	Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 225-36	35.1	40
60	A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease. <i>European Respiratory Journal</i> , <b>2012</b> , 39, 1415-24	13.6	40
59	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 37-47	4	39
58	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2016</b> , 25, 408-417	9.8	38
57	Challenges in the diagnosis and treatment of pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2012</b> , 21, 313-20	9.8	35
56	Action of fenfluramine on voltage-gated K <sup>+</sup> channels in human pulmonary-artery smooth-muscle cells. <i>Lancet, The</i> , <b>1998</b> , 352, 290	4.0	34
55	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2019</b> , 139, 2440-2450	16.7	32
54	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2013</b> , 22, 487-94	9.8	30
53	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 352-359	12.3	26
52	Short-term outcome and predictors of adverse events following pulmonary thromboendarterectomy. <i>World Journal of Surgery</i> , <b>1998</b> , 22, 1029-32; discussion 1033	3.3	25
51	Increased levels of prostaglandin D <sub>2</sub> suggest macrophage activation in patients with primary pulmonary hypertension. <i>Chest</i> , <b>2001</b> , 120, 1639-44	5.3	23
50	Pulmonary arterial hypertension: tailoring treatment to risk in the current era. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	20
49	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 300-309	5.8	19
48	Elevated plasma CXCL12s associated with a poorer prognosis in pulmonary arterial hypertension. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123709	3.7	19
47	Right heart and pulmonary vessels structure and function. <i>Echocardiography</i> , <b>2015</b> , 32 Suppl 1, S3-10	1.5	18
46	Primary pulmonary hypertension is not associated with scleroderma-like changes in nailfold capillaries. <i>Chest</i> , <b>2001</b> , 120, 796-800	5.3	18
45	Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. <i>Chest</i> , <b>1999</b> , 116, 1127-9	5.3	18

44	Medical and surgical treatment options for pulmonary hypertension. <i>American Journal of the Medical Sciences</i> , <b>1998</b> , 315, 179-84	2.2	18
43	Interferon beta related pulmonary arterial hypertension; an emerging worrying entity?. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 284-6	4	14
42	Detection of high-sensitivity troponin in outpatients with stable pulmonary hypertension identifies a subgroup at higher risk of adverse outcomes. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 31-7	3.3	14
41	Percutaneous atrial septostomy with modified butterfly stent and intracardiac echocardiographic guidance in a patient with syncope and refractory pulmonary arterial hypertension. <i>Heart Lung and Circulation</i> , <b>2013</b> , 22, 668-71	1.8	14
40	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , <b>2020</b> , 157, 955-965	5.3	14
39	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 401-408	5.8	12
38	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , <b>2018</b> , 16, 9	5.6	11
37	Bosentan: a novel agent for the treatment of pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , <b>2004</b> , 58, 69-73	2.9	11
36	Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction. <i>Chest</i> , <b>1999</b> , 116, 564-6	5.3	11
35	Induction of heme oxygenase-1 with hemoglobin depresses vasoreactivity in rat aorta. <i>Journal of Vascular Research</i> , <b>1999</b> , 36, 114-9	1.9	11
34	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , <b>2021</b> , 178, 106220	4.6	10
33	Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020914851	2.7	8
32	Management of pulmonary arterial hypertension. <i>Current Opinion in Critical Care</i> , <b>2013</b> , 19, 44-50	3.5	7
31	Pulmonary vascular endothelial responses are differentially modulated after cardiopulmonary bypass. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34, 518-25	3.1	7
30	Medical treatment of pulmonary arterial hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2009</b> , 30, 484-92	3.9	6
29	Migraine with aura following atrial septostomy for pulmonary arterial hypertension. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2007</b> , 4, 55-8		6
28	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. <i>British Journal of Anaesthesia</i> , <b>2021</b> , 126, 774-790	5.4	6
27	Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	6

26	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , <b>2021</b> , 39, 796	4.1	4
25	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 82, 48-55	3.9	4
24	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , <b>2020</b> , 177, 106241	4.6	4
23	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. <i>Chest</i> , <b>2021</b> , 160, 277-286	5.3	4
22	Relief of chronic neuropathic pain through endothelin antagonism. <i>American Journal of Medicine</i> , <b>2010</b> , 123, e7	2.4	3
21	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation	9.5	3
20	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , <b>2009</b> , 62, 1464.e1-1464.e58	1.5	3
19	What is the clinical course of patients hospitalised for COVID-19 treatment Ireland: a retrospective cohort study in Dublin's North Inner City (the Mater 100)		3
18	Hepatopulmonary syndromes: treatment of liver transplantation candidates. <i>Current Opinion in Organ Transplantation</i> , <b>2002</b> , 7, 107-113	2.5	2
17	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , <b>2020</b> , 196, 297-304	8.2	2
16	Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211021036	2.7	2
15	Routine Hematological Parameters May Be Predictors of COVID-19 Severity. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 682843	4.9	2
14	Pulmonary Vascular Disease <b>2013</b> , 603-625		1
13	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2009</b> , 62, 1464.e1-1464.e58	0.7	1
12	Lung transplantation for pulmonary hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2001</b> , 22, 533-40	3.9	1
11	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	1
10	Pulmonary hypertension and home-based (PHAHB) exercise intervention: protocol for a feasibility study. <i>BMJ Open</i> , <b>2021</b> , 11, e045460	3	1
9	"It is the fear of exercise that stops me" - attitudes and dimensions influencing physical activity in pulmonary hypertension patients. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211056509	2.7	0

- 8 Chronic thromboembolic disease and necrotizing granulomatous vasculitis [A case report]. *Respiratory Medicine CME*, **2011**, 4, 149-150
- 7 Medical Treatment of Pulmonary Arterial Hypertension. *Progress in Respiratory Research*, **2012**, 237-245
- 6 Pulmonary Vascular Disease **2005**, 661-680
- 5 Diagnosis and Treatment of Pulmonary Arterial Hypertension **2015**, 4105-4133
- 4 Diagnosis and Treatment of Pulmonary Arterial Hypertension **2014**, 1-33
- 3 An interesting case of progressive dyspnoea and diffuse mediastinal adenopathy in a 25-year-old man. *Breathe*, **2021**, 17, 200289 1.8
- 2 Characteristics of chronic thromboembolic pulmonary hypertension in Ireland. *Pulmonary Circulation*, **2021**, 11, 20458940211048703 2.7
- 1 Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension.. *Breathe*, **2022**, 18, 210168 1.8